Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

A series of nonpeptide somatostatin agonists which bind selectively and with high affinity to somatostatin receptor subtype 2 (sst2) have been synthesized. One of these compounds, L-054,522, binds to human sst2 with an apparent dissociation constant of 0.01 nM and at least 3,000-fold selectivity when evaluated against the other somatostatin receptors. L-054,522 is a full agonist based on its inhibition of forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary-K1 cells stably expressing sst2. L-054,522 has a potent inhibitory effect on growth hormone release from rat primary pituitary cells and glucagon release from isolated mouse pancreatic islets. Intravenous infusion of L-054,522 to rats at 50 microgram/kg per hr causes a rapid and sustained reduction in growth hormone to basal levels. The high potency and selectivity of L-054, 522 for sst2 will make it a useful tool to further characterize the physiological functions of this receptor subtype.

[1]  L. Mahan,et al.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5. , 1993, Molecular pharmacology.

[2]  C. Bruns,et al.  Design, synthesis, and binding affinity of a nonpeptide mimic of somatostatin , 1992 .

[3]  J. Vida,et al.  Conformationally directed drug design : peptides and nucleic acids as templates or targets : based on a symposium sponsored by the Division of Medicinal Chemistry at the 186th Meeting of the American Chemical Society, Washington, D.C., August 28-September 2, 1983 , 1984 .

[4]  A. Patchett,et al.  Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. , 1998, Journal of medicinal chemistry.

[5]  F. Raulf,et al.  Somatostatin analogs for diagnosis and treatment of cancer. , 1993, Pharmacology & therapeutics.

[6]  S. Reichlin.  Somatostatin. , 1983, The New England journal of medicine.

[7]  S. Reichlin.  Somatostatin (First of two parts) , 1983 .

[8]  Y. Patel.  Molecular pharmacology of somatostatin receptor subtypes , 1997, Journal of endocrinological investigation.

[9]  L. Hood,et al.  Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[10]  É. Mezey,et al.  Cell Specific Expression of the SST2A and SST5 Somatostatin Receptors in the Rat Anterior Pituitary. , 1998, Endocrinology.

[11]  S. Melmed,et al.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. , 1997, The Journal of clinical investigation.

[12]  M. Berelowitz,et al.  Molecular cloning and functional expression of a brain-specific somatostatin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Reisine,et al.  Synthesis and conformations of somatostatin-related cyclic hexapeptides incorporating specific .alpha.- and .beta.-methylated residues , 1993 .

[14]  A. Motta,et al.  Cyclic hexapeptides related to somatostatin. Conformational analysis employing 1H-NMR and molecular dynamics. , 2009, International journal of peptide and protein research.

[15]  L. Mahan,et al.  Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin: 28. , 1992, Molecular pharmacology.

[16]  S. Lamberts.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. , 1988, Endocrine reviews.

[17]  S. Melmed,et al.  Structure and function of somatostatin receptors in growth hormone control. , 1997, The Journal of endocrinology.

[18]  Joseph M. Salvino,et al.  De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing beta-D-glucose as a novel scaffolding , 1993 .

[19]  S. Mignani,et al.  Design, synthesis and binding affinities of novel non-peptide mimics of somatostatin/sandostatin® , 1996 .

[20]  Robert P. Sheridan,et al.  Flexibases: A way to enhance the use of molecular docking methods , 1994, J. Comput. Aided Mol. Des..

[21]  M. Greenwood,et al.  All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. , 1994, Biochemical and biophysical research communications.

[22]  D. Johnston,et al.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Lois E. H. Smith,et al.  Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.

[24]  Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.

[25]  D. Veber,et al.  Inferences about the conformation of somatostatin at a biologic receptor based on NMR studies , 1978 .

[26]  V. Mutt,et al.  N‐terminally extended somatostatin: The primary structure of somatostatin‐28 , 1980, FEBS letters.

[27]  L. Kvols,et al.  Advances in the use of somatostatins in the management of endocrine tumors. , 1996, Current opinion in oncology.

[28]  J. Epelbaum.  Somatostatin in the central nervous system: Physiology and pathological modifications , 1986, Progress in Neurobiology.

[29]  D. Coy,et al.  The New Pharmacology of Somatostatin and its Multiple Receptors , 1993, The Journal of pediatric endocrinology.

[30]  C. Papageorgiou,et al.  A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure , 1996 .

[31]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[32]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[33]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[34]  F. D. Leeuw,et al.  The relationship between proton-proton NMR coupling constants and substituent electronegativities—I : An empirical generalization of the karplus equation , 1980 .

[35]  L. Pradayrol,et al.  Effects of somatostatin-14 and somatostatin-28 on bombesin-stimulated release of gastrin, insulin, and glucagon in the dog. , 1981, Endocrinology.

[36]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[37]  T. Reisine,et al.  Main chain and side chain chiral methylated somatostatin analogs : syntheses and conformational analyses , 1992 .

[38]  G. Krejs.  Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motility. , 1986, Scandinavian journal of gastroenterology. Supplement.

[39]  S. Seino,et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  É. Mezey,et al.  Immunohistochemical Localization of Somatostatin Receptor SST2A in the Rat Pancreas. , 1997, Endocrinology.

[41]  C. Saper,et al.  Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. , 1992, The Journal of biological chemistry.

[42]  L. Mahan,et al.  Method for identifying ligands that bind to cloned Gs- or Gi-coupled receptors , 1991, Molecular and Cellular Neuroscience.

[43]  D. Coy,et al.  Three-dimensional quantitative structure-activity relationships of somatostatin analogues. 1. Comparative molecular field analysis of growth hormone release-inhibiting potencies. , 1995, Journal of medicinal chemistry.

[44]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[45]  D. Coy,et al.  Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. , 1994, Biochemical and biophysical research communications.

[46]  N. Ling,et al.  Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion , 1981, Nature.